|
|
||||||||




Departments of Microbiology and Immunology,
* Pharmacology, and Center for Substance Abuse Research,
Temple University School of Medicine, Philadelphia, Pennsylvania
Correspondence: Toby K. Eisenstein, Ph.D., Department of Microbiology and Immunology, Temple University School of Medicine, 3400 North Broad Street, Philadelphia, PA 19140. E-mail: tke{at}astro.ocis.temple.edu
In this study we investigated the capacity of morphine to modulate
expression of cytokines in peritoneal macrophages. Mice were implanted
subcutaneously with a 75-mg morphine slow-release pellet, and 48 h
later resident peritoneal macrophages were harvested. Control groups
received placebo pellets, naltrexone pellets, or morphine plus
naltrexone pellets. Adherent cells were stimulated with
lipopolysaccharide (LPS: 10 µg/mL) plus interferon-
(IFN-
: 100
units/mL) to induce cytokine production. After 24 h RNA was
extracted for analysis of cytokine mRNA levels by reverse
transcriptase-polymerase chain reaction, or supernatants were collected
after 48 h for determination of cytokine production by
enzyme-linked immunosorbent assay (ELISA). Morphine enhanced mRNA
expression of interleukin (IL)-12 p40 and tumor necrosis factor
(TNF-
) compared with controls, whereas IL-10 levels were unchanged
by drug treatment. ELISA data showed that both IL-12 p40 and p70 were
increased by morphine. The enhancement of IL-12 at both the mRNA and
protein levels was antagonized by naltrexone, indicating that the
modulation of this cytokine by morphine is via a classic opioid
receptor. These results are particularly interesting in light of our
previous observation that 48 h after morphine pellet implantation,
the peritoneal cavity is colonized with gram-negative and other enteric
bacteria. The enhancement of IL-12 by morphine might be related to
morphine-induced sepsis.
Key Words: interleukin-10 interferon-
naltrexone
This article has been cited by other articles:
![]() |
C. Borner, J. Kraus, A. Bedini, B. Schraven, and V. Hollt T-Cell Receptor/CD28-Mediated Activation of Human T Lymphocytes Induces Expression of Functional {micro}-Opioid Receptors Mol. Pharmacol., August 1, 2008; 74(2): 496 - 504. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Happel, A. D. Steele, M. J. Finley, M. A. Kutzler, and T. J. Rogers DAMGO-induced expression of chemokines and chemokine receptors: the role of TGF-{beta}1 J. Leukoc. Biol., April 1, 2008; 83(4): 956 - 963. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. M. Pello, B. Duthey, D. Garcia-Bernal, J. M. Rodriguez-Frade, J. V. Stein, J. Teixido, C. Martinez-A., and M. Mellado Opioids Trigger {alpha}5beta1 Integrin-Mediated Monocyte Adhesion J. Immunol., February 1, 2006; 176(3): 1675 - 1685. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Greeneltch, A. E. Kelly-Welch, Y. Shi, and A. D. Keegan Chronic Morphine Treatment Promotes Specific Th2 Cytokine Production by Murine T Cells In Vitro via a Fas/Fas Ligand-Dependent Mechanism J. Immunol., October 15, 2005; 175(8): 4999 - 5005. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. N. Johnston, E. D. Milligan, J. Wieseler-Frank, M. G. Frank, V. Zapata, J. Campisi, S. Langer, D. Martin, P. Green, M. Fleshner, et al. A Role for Proinflammatory Cytokines and Fractalkine in Analgesia, Tolerance, and Subsequent Pain Facilitation Induced by Chronic Intrathecal Morphine J. Neurosci., August 18, 2004; 24(33): 7353 - 7365. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Friedman, C. Newton, and T. W. Klein Microbial Infections, Immunomodulation, and Drugs of Abuse Clin. Microbiol. Rev., April 1, 2003; 16(2): 209 - 219. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Limiroli, L. Gaspani, A. E. Panerai, and P. Sacerdote Differential morphine tolerance development in the modulation of macrophage cytokine production in mice J. Leukoc. Biol., July 1, 2002; 72(1): 43 - 48. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wang, R. Charboneau, S. Balasubramanian, R. A. Barke, H. H. Loh, and S. Roy The immunosuppressive effects of chronic morphine treatment are partially dependent on corticosterone and mediated by the {micro}-opioid receptor J. Leukoc. Biol., May 1, 2002; 71(5): 782 - 790. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |